NCT07154485
Investigator Initiated Study for the Safety and Efficacy in Frontotemporal Dementia
Not Yet Recruiting · Phase 2 · Hee-Jin Kim · registry updated 2025-09-04
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
The purpose of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD), immunogenicity, and efficacy of multiple intravenous administrations of the investigational drug NS101, compared to placebo, in patients with semantic variant primary progressive aphasia (svPPA), a subtype of frontotemporal dementia (FTD)
Inclusion
- Participants diagnosed at screening with mild to moderate frontotemporal dementia, semantic variant (svFTD), defined by a CDR® Plus NACC FTLD Sum of Boxes (SOB) score between 4.5 and 15.5.
- Participants confirmed to be amyloid-negative based on Amyloid PET scan or CSF results within the past 36 months.
Exclusion
- Participants with other degenerative brain diseases as determined by the investigator
- Participants with other neurological disorders and uncontrolled acute disease